REDWOOD CITY, Calif., July 17 (UPI) -- Threshold Pharmaceuticals said Monday trials of its potential treatment for enlarged prostate did not meet primary endpoints.
"We are of course disappointed by these results," said Barry Selick, Threshold's CEO. "Although we will continue to analyze the data from these trials, we do not expect that (these) efficacy data, combined with the liver effects that we reported earlier, will support a path for development of TH-070 for (benign prostatic hyperplasia). Therefore, we believe it is in the best interest of the company and our shareholders to discontinue the TH-070 BPH program at this time."
The phase 2 and phase trials did not meet their endpoints of symptomatic improvement. The phase 2 trial did not show a statistically significant dose response relationship and the phase 3 trial did not show a difference between TH-070 and placebo.
Selick said Threshold would continue to seek product candidates that could broaden their portfolio. The company's glufosfamide, a potential treatment for pancreatic cancer, is in phase 2 and phase 3 trials. Results of those studies are expected by the end of the year.
